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Abstract ENDURALIFETM-powered cardiac resynchro-
nisation therapy defibrillator (CRT-D) devices were the
subject of an evaluation by the National Institute for Health
and Care Excellence, through its Medical Technologies
Evaluation Programme, for the treatment of heart failure.
Boston Scientific (manufacturer) submitted a case for the
adoption of the technology, claiming that it has a longer
battery life resulting in a longer time to CRT-D replace-
ment. Other claimed benefits were fewer complications
associated with replacement procedures, fewer hospital
admissions, less time spent in hospital and reduced demand
on cardiology device implantation rooms. The submission
was critiqued by Cedar, an external assessment centre. The
submitted clinical evidence showed that ENDURALIFE-
powered devices implanted during the period 2008–2010
were superior, in terms of longevity, to other devices at that
time. Submitted economic evidence indicated that, because
of a reduction in the need for replacement procedures,
ENDURALIFE-powered devices were cost saving when
compared to comparator devices. Cedar highlighted
uncertainty of the applicability of the clinical evidence to
devices marketed today. The Medical Technologies Advi-
sory Committee noted that this was unavoidable due to the
follow-up time required to study battery life. Clinical
experts noted that increased battery life is an important
patient benefit. However, centres use devices from multiple
manufacturers to negate pressure on clinical services in the
event of a major device recall. The clinical and economic
evidence showed benefits to the patient, and further anal-
ysis requested by the committee suggested that ENDUR-
ALIFE-powered CRT-Ds may save between £2120 and
£5627 per patient over 15 years through a reduction in the
need for replacement procedures. ENDURALIFE-powered
CRT-D devices received a positive recommendation in
Medical Technologies Guidance 33.
Key Points for Decision Makers
The clinical evidence submitted by the manufacturer
is robust and shows superiority, in terms of
longevity, of ENDURALIFE-powered CRT-D
devices over other CRT-D devices implanted in the
period around 2008–2010. Cost-modelling showed
that longevity and price of the CRT-D device have
the greatest effect on overall treatment costs.
ENDURALIFE-powered CRT-D devices were
shown to be cost saving compared to other CRT-D
devices implanted around 2008–2010.
CRT-D device technology evolves rapidly across
different manufacturers. Innovations are likely to
include other components of the device and not the
battery alone. It is uncertain if the evidence has
direct applicability to CRT-D devices marketed
today as by the time evidence is produced the
devices may no longer be available.
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1 Introduction
The National Institute for Health and Care Excellence
(NICE) evaluates new or innovative medical technologies
through its Medical Technologies Evaluation Programme
(MTEP). The programme generates guidance on diagnostic
technologies and medical devices in addition to providing
support for technology adoption to the National Health
Service (NHS) [1].
NICE Medical Technologies Guidance (MTG) is a
published completed evaluation of a new or innovative
medical technology. The process has previously been
described in detail [2]. Briefly, NICE publish a scope for
the guidance that is followed by a submission from the
technology’s manufacturer. In this submission, the manu-
facturer will make a case for adoption of the technology
and will provide both clinical and economic evidence to
support their claimed benefits. The submitted evidence is
reviewed and critiqued by an external assessment centre
(EAC), with expertise in medical technology evaluation.
The EAC presents their review and critique in an assess-
ment report, which, in conjunction with the manufacturer’s
submission, is used by the Medical Technologies Advisory
Committee (MTAC) during its decision process.
This paper summarises an assessment report by an EAC
and shows how it was used by NICE to inform the MTG on
ENDURALIFETM-powered cardiac resynchronisation
therapy defibrillator (CRT-D) devices for treating heart
failure. The paper is part of a series that provide an insight
into the development of NICE MTG [2]. Cedar, a health-
care technology research centre formed through collabo-
ration between Cardiff and Vale University Health Board
and Cardiff University, was the EAC responsible for pro-
ducing this assessment report. ENDURALIFE-powered
CRT-D devices are manufactured by Boston Scientific.
2 Background to the Condition and Technology
Heart failure is a condition where an abnormality in cardiac
function results in an impairment of the heart to pump
blood efficiently [3]. Specifically, the condition arises from
a structural or functional disorder of the heart, which
impairs the ventricle’s ability to fill or eject blood [4].
Heart failure can be classed as chronic or acute and can
occur as a result of left ventricular systolic dysfunction
(LVSD) or diastolic dysfunction where there is a preserved
left ventricular ejection fraction (LVEF) [5].
Recent work combining prevalence figures with popu-
lation estimates suggests that in the UK[ 308,000 men
and 250,000 women are living with heart failure [6]. The
highest prevalence of heart failure was observed in Wales
and in North East England. Heart failure prevalence
increased with age and was most prevalent in people aged
C 75 years.
Current NICE technology appraisal guidance recom-
mends the use of CRT-D devices as treatment options for
people with heart failure. The guidance specifically rec-
ommends CRT-Ds for use in people with heart failure who
have left ventricular dysfunction and an LVEF of B 35%,
according to New York Heart Association (NYHA) class,
QRS interval and presence of left bundle branch block [7].
CRT-D devices combine cardiac resynchronisation
therapy, for cardiac pacing, and a defibrillator for ventric-
ular arrhythmia treatment [7]. The CRT-D generator is
combined with leads that allow sensing of the heart’s
electrical activity and deliver the electrical energy to the
atria and ventricles of the heart. Power for the CRT-D
comes from a battery which is sealed within the device
itself. A CRT-D makes a small, but virtually continuous
demand on battery energy for ventricular resynchronisa-
tion. In addition, where a life-threatening arrhythmia is
detected by the CRT-D, a defibrillation shock delivers a
large amount of energy via a capacitor to restore normal
heart rhythm. Therefore, there are two distinct patterns of
demand for energy placed on the battery. All CRT-D bat-
teries deplete over time and the rate of depletion depends
on factors such as the energy required for pacing, the
number of shocks the CRT-D has had to deliver and
whether settings such as remote monitoring are enabled.
An elective replacement indicator (ERI) indicates that a
limited safe quantity of battery capacity (e.g. for 3 months’
operation) remains and that the whole generator must be
replaced; the battery cannot be removed from the sealed
CRT-D.
ENDURALIFE battery technology was designed by
Boston Scientific in an effort to extend the working life of
their CRT-D devices. The technology uses lithium man-
ganese dioxide (Li/MnO2) as its battery chemistry, which
according to the manufacturer, is less susceptible to vari-
ations in voltage and resistance associated with early bat-
tery depletion. The ENDURALIFE battery has a large
capacity of 2.0 Ampere-hours (Ah). In addition, the man-
ufacturer claims that the microprocessor and circuitry of
ENDURALIFE-powered CRT-Ds have been designed to
use less current and that ENDURALIFE-powered CRT-Ds
are both smaller and thinner than previous CRT-Ds.
ENDURALIFE as a brand was launched by Boston Sci-
entific in 2015 but the technology has been used in all their
CRT-D devices since the COGNIS device in 2008. CRT-D
devices are Class III medical devices under the medical
devices directive and have CE mark status [8].
In their submission to NICE, the manufacturer claimed
the following benefit to the patient: extended CRT-D
longevity increases the interval between CRT-D
178 J. M. Evans et al.
replacements. This would be beneficial for heart failure
patients since CRT-D replacement is an invasive surgical
procedure known to have a greater risk of complications
than de novo (initial) CRT-D implant procedures.
The manufacturer claimed the following benefits to the
healthcare system: a reduced chance of needing earlier
CRT-D replacement will lead to savings through a reduc-
tion in hospital admissions; more efficient use of cardiol-
ogy device implantation facilities as reduced replacement
rates will allow new patients to be implanted within the
same resource constraints, supporting the implementation
of NICE’s technology appraisal guidance [7], and bridging
the gap with recommended levels of CRT-D implants in
the UK; a reduction in costs associated with replacement
such as post-operative complications and infections.
3 Decision Problem (Scope)
To focus their submission, the manufacturer must define
and follow a decision problem, which is presented in a
population, intervention, comparator, outcomes (PICO)
table. The PICO table generated by the manufacturer was
consistent with the final scope, published by NICE in May
2016 [8].
3.1 Population
In their decision problem, the manufacturer identified
‘‘patients undergoing CRT-D device implantation for heart
failure’’ as their target population. This was in line with
previously published NICE technology appraisal guidance
[7].
3.2 Intervention
The scope for intervention included ENDURALIFE-pow-
ered CRT-D devices [8].
3.3 Comparator
The manufacturer identified any CRT-D that did not
incorporate ENDURALIFE battery technology as a com-
parator [8]. Comparators were therefore typically CRT-Ds
from other manufacturers.
3.4 Outcomes
The decision problem included a number of outcomes. The
included outcomes were identified by the manufacturer to
provide evidence for their submitted claimed benefits and
included device-based, patient-related, clinical and
resource use outcomes.
Device-based outcomes were relevant to all CRT-Ds
and included device survival, battery survival (or time to
ERI) and CRT-D component failure.
Patient outcomes included satisfaction and quality of
life, while inpatient admissions and bed days (due to
device-related interventions) were considered as resource
use outcomes.
Clinical outcomes included device-related adverse
events, number of invasive procedures (including replace-
ment surgeries), incidence of complications (due to
replacement procedures for battery depletion and/or CRT-
D component failure) and death. The EAC recognised that
the complication risks associated with CRT-D replacement
surgery are common to any CRT-D and not just those that
contain ENDURALIFE battery technology. Therefore, this
evidence could be coupled with evidence on longevity or
replacement rates of CRT-Ds with ENDURALIFE battery
technology, in order to assess the manufacturer’s claimed
benefits. From a healthcare perspective, if the device was
shown to have extended longevity, this could potentially
reduce costs associated with hospital admissions and bed
days. This would be dependent on the number of generator
replacements a patient requires over their lifetime.
4 Review of Clinical Effectiveness Evidence
4.1 Manufacturer’s Review of Clinical Effectiveness
Evidence
The manufacturer submitted clinical evidence as outlined
in the scope [8]. The manufacturer submitted a total of
seven retrospective case series studies, which focused on
CRT-D longevity, from six sources. Five of the included
studies were available as full papers [9–13], two studies
were reported as conference abstracts only [14, 15] and one
study was reported in two papers at two different time-
points [9, 10]; only the latest paper has been summarised
(Table 1). In addition to submitting evidence on CRT-D
longevity, the manufacturer also submitted a total of 19
studies to highlight the complications associated with
implantable cardioverter defibrillator (ICD) and CRT-D
replacement procedures, as a whole. These papers were not
device or manufacturer specific. The manufacturer’s sub-
mission of clinical evidence also included product perfor-
mance reviews (PPRs). These reviews are produced by the
five manufacturers of CRT-Ds in response to a recom-
mendation by the US Heart Rhythm Society Task Force
[16]. The PPRs aim to report device malfunctions based
only on data derived from explanted devices returned to the
manufacturer. Based on the status of CRT-Ds observed
during follow-up and at device return, actuarial statistical
methods are used to derive a cumulative survival
ENDURALIFE-Powered Cardiac Resynchronisation Therapy Defibrillator Devices 179
probability. Therefore, comparing PPRs across manufac-
turers may permit comparisons of CRT-D longevities. The
PPRs submitted suggested that in the majority of cases the
replacement of their CRT-Ds was due to battery depletion
and not device malfunctions. The manufacturer also
included a comprehensive description of adverse events
identified in the US Food and Drug Administration (FDA)
Manufacturer and User Facility Device Experience
(MAUDE) and UK Medicines and Healthcare Products’
Regulatory Agency (MHRA) databases. The identified
adverse events highlight that CRT-Ds are Class III medical
devices with indications in patients at risk of serious
morbid incident or mortality, and as such can generate a
large number of adverse events.
4.2 EAC Critique of Clinical Effectiveness Evidence
The manufacturer conducted two separate literature sear-
ches. One retrieved evidence for device longevity and the
other retrieved evidence on the incidence of complications
associated with device replacement. The manufacturer’s
search strategies for PubMed and Cochrane were assessed
in accordance with the Peer Review of Electronic Search
Strategies (PRESS) checklist [17]. The EAC considered the
search strategies could be improved, and carried out its
own search of the literature and adverse events, in addition
to citation tracking. The EAC’s literature search results
were reported using Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA)
Table 1 Summary of evidence submitted by the manufacturer
Study reference,
country, and follow-up
CRT-Ds in study Device survival Limitations
Alam et al. (2016) [9]
USA
Mean follow-up = 3.4
years (SD ±2.1);
median follow-up =
3.7 years (IQR 1.6,
5.0)
ENDURALIFE-powered BSC (n = 122),
non-ENDURALIFE-powered BSC (n =
51), MDT (n = 391), SJM (n = 57)
Rates of replacement due to
battery depletion (ERI):
BSC: 16%, MDT: 51%,
SJM: 53% (p\ 0.001)
Of 173 BSC devices studied, 122 were
ENDURALIFE-powered, so
comparisons by manufacturer do not
have complete applicability to the
scope
Ellis et al. (2016) [11]
USA
Mean follow-up = 3
years (SD ± 1.3)
BSC (n = 322; of which 97% were
ENDURALIFE-powered), MDT (n =
794), SJM (n = 186)
Device survival and out of
service reason: ERI-BSC:
0.3%, MDT: 13.5% and
SJM: 3.8%
Device names were not reported in the
paper itself. Proportions of devices
were obtained by the manufacturer
through direct contact with the authors
Landolina et al. (2015)
[12]
Italy
Median follow-up = 43
months (IQR 18, 53)
ENDURALIFE-powered BSC (n = 291),
non-ENDURALIFE-powered BSC (n =
317), MDT (n = 798), SJM (n = 172),
BTK (n = 49), SOR (n = 99)
Device longevity at 5 years:
BSC: 88 %, SJM: 75 %,
MDT: 52%
Of 608 BSC devices studied, 291 were
ENDURALIFE-powered. However,
data presented on device longevity at 5
years is based on recent generation
devices and all BSC devices were
COGNIS devices. These are
ENDURALIFE-powered
von Gunten et al. (2015)
[13]
The Netherlands and
Switzerland
Median follow-up = 4.4
years (IQR, 2, 7.3)
ENDURALIFE-powered BSC (n = 102),
non-ENDURALIFE-powered BSC (n =
39), other CRT-Ds including MDT and
SJM (n = 1143)
Device longevity at 5 years:
BSC: 97.6%, SJM: 45.3%,
MDT: 74.1%, BTK: 76.2%
Device longevity at 6 years:
BSC: 97.6%, SJM: 26.5%,
MDT: 46.3%, BTK: 44.9%
The main paper does not state whether or
not BSC devices are ENDURALIFE-
powered; however, a supplementary
table reports the longevity for 76
ENDURALIFE-powered COGNIS
devices
Lau et al. (2015) [14]
UK
No mean or median
follow-up stated
ENDURALIFE-powered BSC (n = 27),
MDT (n = 62), SJM (n = 66)
BSC survival at 6 years:
100%
Time to reach ERI for
comparator devices: SJM:
2.8 years, MDT: 2.5 years
This study is only available as an
abstract. Many details are not reported
including patient characteristics,
number of subjects per group and
average follow-up
Williams and Stevenson
(2014) [15]
Lebanon
No mean or median
follow-up stated
ENDURALIFE-powered BSC (n = 51),
non-ENDURALIFE-powered BSC (n =
2), MDT (n = 28), SJM (n = 10)
Devices reaching ERI at 4
years: BSC: 1.9%, SJM:
10%, MDT: 50%
This study is only available as an
abstract. Many details are not reported
including values for some outcome data
BSC Boston Scientific, BTK Biotronik, CRT-D(s) cardiac resynchronization therapy defibrillator(s), ERI elective replacement indicators, IQR
inter-quartile range, MDT Medtronic, SD standard deviation, SJM St. Jude Medical, SOR Sorin
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methodology [18] (Fig. 1). Following its own searching,
the EAC was satisfied that the manufacturer identified all
the relevant literature for this technology at the time of
writing their submission.
The studies on device longevity included by the manu-
facturer were consistent with the decision problem and the
manufacturer took the reasonable step of excluding studies
where ENDURALIFE-powered CRT-Ds comprised fewer
than 50% of devices in the study. Participants in the
included studies underwent implantation from 2008
onwards, the year that ENDURALIFE technology became
available. One study included patients implanted with
CRT-Ds between 1994 and 2014, but a supplement to this
study separately reports the longevity of ENDURALIFE-
powered COGNIS CRT-Ds [13]. There are a few limita-
tions with the evidence submitted on device longevity. One
limitation was that not all Boston Scientific CRT-Ds are
powered by ENDURALIFE technology. This was further
confounded by the fact not all studies have reported which
CRT-Ds have been studied [11, 15]. To address this
problem, the manufacturer contacted the authors and
obtained the number of ENDURALIFE-powered CRT-Ds
in the studies.
Of the manufacturer’s submitted studies reporting
complications due to replacement procedures (n = 19),
three were systematic reviews [19–21] and included data
from the majority of the primary studies submitted. The
EAC selected the three systematic reviews, in addition to
two primary studies [22, 23], which were not included in
the systematic reviews, as evidence on complications.
These studies also included data on ICD replacement.
However, the EAC considered the applicability of CRT-D
replacement procedures was limited only to a small extent
by the inclusion of data for ICD replacement because in
either case the procedure is similar.
The manufacturer submitted five PPRs in total; one for
each manufacturer of CRT-Ds. PPRs have a few limita-
tions: Boston Scientific PPRs are based on data from the
US only; not all devices are returned to the manufacturer
following explantation; PPR analysis assumes that a device
is in service unless otherwise indicated, which could
overestimate CRT-D longevity if devices that have not
been returned to the manufacturer are recorded as in ser-
vice instead of lost to follow-up; the definition of normal
battery depletion is different for each manufacturer and
means that two devices from different manufacturers that
Records idenﬁed through 
database searching – duplicates 
removed 
(n =476)
Addional records idenﬁed 
through other sources 
(supplementary methods)
(n = 10)
First screen: tle/abstract 
(n = 486)
Records excluded on
tle/abstract 
(n = 465)
Second screen: assessed for 
eligibility at full text
(n = 21)
Publicaons included in clinical 
evaluaon
(n = 7 papers/abstracts
n = 6 studies)
Full-text/abstracted 
arcles excluded, with 
reasons 
(n = 14)
Includes:
- Unable to determine if 
the CRT-D device was 
ENDURALIFE-powered 
(n=11)
- No ENDURALIFE-powered 
CRT-D devices included 
(n=2)
- Very low number of 
ENDURALIFE-powered 
CRT-D devices (n=1)
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram showing the EAC’s literature search results.
CRT-D cardiac resynchronisation therapy defibrillator
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reach a point of battery failure at the same length of follow-
up may be classified as normal battery depletion or pre-
mature battery depletion (a malfunction). For these rea-
sons, the EAC concluded that the PPRs served to indicate
that ERI rather than malfunction is the most common
reason for CRT-D replacement.
The manufacturer’s description of adverse events related
to ENDURALIFE-powered CRT-Ds, as returned from a
search of the FDA MAUDE and MHRA databases, was
comprehensive. The search returned [ 8000 adverse
events, whilst the EAC’s search for adverse events in the
same databases identified 2677 events. The EAC under-
stands the manufacturer is likely to be highly vigilant for
adverse events related to the implantable devices it markets
and has likely identified more adverse events through its
own active surveillance and close communication with
regulatory bodies and clinical sites.
4.3 EAC Conclusions on the Clinical Evidence
The manufacturer’s submission of published studies of
CRT-D longevity provides head-to-head comparisons of
ENDURALIFE-powered CRT-D devices with contempo-
rary comparator CRT-D devices. Weaknesses in the evi-
dence included limited applicability of some studies to the
decision problem, retrospective analysis and that it is not
possible to determine why study participants were
implanted with a CRT-D device from a particular
manufacturer.
The EAC considers that battery capacity is an important
factor, which may potentially determine CRT-D device
longevity, but also that it does not act in isolation and other
CRT-D device components also play an important role in
device longevity. Battery capacity for ENDURALIFE-
powered CRT-Ds has been reported as 2.0 Ah compared
with 1.0 Ah for Medtronic CRT-Ds and undisclosed for St
Jude Medical CRT-Ds [12]. PPRs submitted by the man-
ufacturer demonstrate that normal battery depletion is the
main reason for CRT-D replacement, and not device mal-
functions. However, due to limitations and variability
across manufacturers in the methods behind PPRs, the
EAC acknowledged that the published studies of longevity
presented more robust data on longevity than the PPRs.
The EAC accepted the manufacturer’s submission of
evidence on the rate of complications following CRT-D
replacement. In addition, the EAC noted that the high
number of observed adverse events is likely, considering
that CRT-Ds are Class III medical devices, used in people
with heart failure and potential co-morbidities. However,
the EAC has seen no evidence that ENDURALIFE-pow-
ered CRT-Ds present a particular risk of adverse events
compared to comparator CRT-Ds.
The EAC found that the clinical evidence submitted by
the company was acceptably robust and reflects the per-
formance of ENDURALIFE-powered CRT-Ds implanted
in the period 2008–2010, showing their superiority at that
time in terms of longevity. However, it is uncertain whe-
ther it has direct applicability to CRT-Ds marketed today.
It is likely that different manufacturers have each under-
taken their own development. Such innovations are unli-
kely to be limited to the battery alone, but to other
components of the CRT-D (e.g. capacitor, microprocessor,
etc.) and how it interacts with the heart. Devices marketed
today may have better longevity than their predecessors
studied in the included longevity studies. Finally, whether
differences in longevity between ENDURALIFE-powered
CRT-Ds and comparators lead to a reduction in replace-
ment procedures depends on patient life expectancy.
5 Economic Evidence
5.1 Manufacturer’s Economic Submission
The manufacturer’s economic submission included seven
studies, two of which were published in full [24, 25], two
full papers were academic in confidence (unpublished
work) and three were conference abstracts [26–28]. All the
manufacturer’s selected economic studies were based out-
side of the UK apart from one conference abstract [28].
Therefore, the manufacturer generated a de novo economic
model similar in structure to a model described in one of
the unpublished papers.
Clinical model inputs on event-free battery survival
were identified from an unpublished economic study,
which appears to be a sub-set of the same sample reported
in a previous publication [12]. Data inputs for the model on
cumulative probability of patient survival were identified
from another study [29]. The technology considered is the
ENDURALIFE-powered CRT-D from a previously pub-
lished study [12]. This study also included data on other
non ENDURALIFE-powered Boston Scientific CRT-Ds in
addition to comparator devices from Medtronic and St Jude
Medical. Data on complications associated with replace-
ment procedures were identified from a study submitted as
part of the manufacturer’s clinical evidence [19].
The de novo model was a decision tree with a 6-year
time horizon from an NHS perspective with ENDUR-
ALIFE-powered CRT-Ds as the intervention and CRT-Ds
manufactured by Medtronic and St Jude Medical as com-
parators. For each CRT-D manufacturer there is a branch
for complications or no complications. Both these cases
have further branches for death, replacement or no
replacement at 1 year and at each subsequent year. Key
assumptions of the model include: all device capital costs
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are equal; all manufacturer warranties are equal; patients
attend 6-monthly outpatient follow-up appointments with
an additional post-procedure appointment; data from pub-
lished literature on devices implanted between 2008 and
2010 can be applied to the latest generation devices cur-
rently available from the same manufacturers.
To factor in improvements over time of comparator
CRT-Ds, an estimated percentage improvement in pro-
jected battery survival was applied to Medtronic CRT-Ds
only. The manufacturer’s base case showed that Boston
Scientific ENDURALIFE-powered, St. Jude Medical and
Medtronic CRT-Ds cost £22,322, £27,309 and £29,158,
respectively per patient over 6 years. The manufacturer
therefore estimated that using an ENDURALIFE-powered
CRT-D would save £4986 and £6836 per patient over a
6-year period when used in place of a Medtronic or St Jude
Medical CRT-D, respectively.
5.2 Critique of Economic Evidence
The manufacturer’s literature search was limited to three
publicly available databases and therefore did not include
all the databases specified by NICE in its submission
template. Search terms used by the manufacturer were
somewhat limited. Therefore, the EAC conducted its own
search using the recommended databases and more com-
prehensive search terms. Following its own literature
search, the EAC was satisfied that the manufacturer’s
search results were reasonable. The population used by the
manufacturer in its selection of economic evidence differed
from the population specified in the decision problem. The
EAC acknowledged that the manufacturer’s broader pop-
ulation definition is likely to be as a result of a lack of
detail in the published evidence on the specific criteria used
to define heart failure and CRT-D use from the relevant
NICE technology appraisal guidance [7]. The EAC
excluded three papers that had been included by the man-
ufacturer [24–26] as they were outside of scope [8]. The
manufacturer described the included economic studies and
carried out a quality assessment of each. Finally, due to the
rapidly evolving technology the published economic evi-
dence relates to devices no longer marketed.
5.3 Critique of the De Novo Model
The manufacturer did not approach clinical advisers to
assess the applicability of clinical or resource inputs used
in the model. They performed internal and external quality
assurance to ensure the model performs as intended. The
manufacturer conducted a one-way sensitivity analysis to
identify thresholds where the model becomes cost-neutral.
Their analysis explored differences in device survival and
device cost.
The 6-year time horizon was a limitation of the model
and potentially exaggerates the cost saving of a slightly
longer-lasting device. The EAC considered that it is
unclear whether a small difference in CRT-D longevity
across suppliers would result in a fewer total number of
replacement procedures over the entire lifetime of a
patient, but was unable to identify a reliable study of
patient life expectancy in the CRT-D-implanted popula-
tion. For this reason, the EAC obtained patient survival
data from the National Institute for Cardiovascular Out-
comes Research (NICOR) following expert advice and
replaced the data used by the manufacturer [29].
ENDURALIFE-powered CRT-Ds remained cost saving
when using the manufacturer’s base-case device cost. At
the lowest and highest list prices, for each of the three
manufacturers, ENDURALIFE-powered CRT-Ds become
more expensive than those from Medtronic; however, they
remain cost saving compared with those from St Jude
Medical. The MTAC judged that the 6-year time horizon
gave rise to uncertainty surrounding the cost case. Data on
patient survival was obtained from NICOR and the EAC
carried out extrapolation of CRT-D lifespan to 15 years.
Using the extrapolated data and the manufacturer’s base-
case average selling price, the EAC calculated ENDUR-
ALIFE-powered CRT-Ds cost £28,234 compared with
£30,354 and £33,861 per patient over 15 years for St Jude
Medical and Medtronic CRT-Ds, respectively, and could
save between £2120 and £5627 per patient over 15 years in
patients aged 50–84 years.
The company based the costs of technologies on the
assumption that all the devices cost the same. In the model,
the device cost is a key driver and therefore this was a
significant weakness of the model. The EAC obtained list
prices from Boston Scientific, St. Jude Medical and Med-
tronic and carried out threshold analysis allowing price
differences between the devices and calculated the
threshold at which the intervention becomes cost saving
compared to the comparators. The results showed that,
accepting all else in the model, ENDURALIFE-powered
CRT-Ds remain cost saving until they are £4858 and £3858
more expensive to purchase than Medtronic and St Jude
Medical CRT-Ds, respectively.
The EAC sought expert clinical advice on rates of
complications associated with replacement procedures and
included a Danish cohort study, which provided the nec-
essary data, based on the recommendation of the expert
advice [30]. The EAC considered that the manufacturer’s
sensitivity analysis covered the range of different compli-
cations reported in the cohort study apart from rate of
infection. The EAC included the rate of infections from the
cohort study in the model and the effect was negligible.
The EAC also obtained information on warranties from
the manufacturers and carried out analysis based on this.
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ENDURALIFE-powered CRT-Ds remained cost saving.
The EAC also substituted the payment by results (PbR)
tariff, used by the manufacturer for procedure costs, with
NHS reference costs from 2014–2015. This increased the
cost of ENDURALIFE-powered CRT-Ds from £22,322 in
the base case to £30,957. This was still cost saving com-
pared to Medtronic and St Jude Medical CRT-Ds (£37,087
and £35,429, respectively) but was less so than in the
manufacturer’s base case.
6 NICE Guidance
6.1 Provisional Recommendations and Consultation
In September 2016, MTAC convened to make provisional
MTG recommendations on ENDURALIFE-powered CRT-D
devices, with the assistance of the EAC, two clinical expert
advisors, and a patient representative. The committee consid-
ered that ENDURALIFE-powered CRT-Ds have a greater
battery capacity and longer battery life compared with other
CRT-Ds available at the time of the published studies. It noted
that, because of the follow-up time needed to study battery life,
the retrospective, observational studies presented included
CRT-Ds thatwereno longermarketed. In the absenceof dataon
currently marketed devices, the committee was advised by
experts that the company’s claims relating to battery life and the
ENDURALIFEbattery technology have been borne out in their
own subsequent clinical experience, as well as in the published
literature. The committee was advised that replacement pro-
cedures are associated with a risk of serious complications and
that complications are more common in replacement than pri-
mary implants. Infection can havemajor consequences in terms
of patient morbidity and resource use, including the need for
hospital admission that may last days or weeks. The committee
heard from a patient expert that replacement procedures have a
detrimental impact on quality of life.
The committee further discussed issues concerning NHS
resources and costs. Battery depletion accounts for 80–90%
of CRT-D replacements. The committee heard from
experts that, despite increased battery life being an
important patient benefit, it is standard practice for a single
centre to use CRT-Ds from more than one manufacturer.
The rationale is to spread the risk of undue pressure on
clinical services in the face of possible future device-re-
lated technical failure necessitating recall and replacement.
In view of this important consideration, professional advice
was that it was unwise for a department to rely entirely on
the use of a CRT-D from a single manufacturer.
Regarding costs, the committee was advised that the
average selling prices used in the company’s base case was
a better reflection of what the NHS pays for CRT-Ds;
furthermore, the committee concluded that it would be
difficult to ascertain actual NHS prices for ENDURALIFE-
powered and comparator CRT-Ds. Overall, the committee
concluded that using ENDURALIFE-powered CRT-Ds in
patients with heart failure is likely to cut costs by reducing
the number of replacement procedures.
Following the meeting, draft guidance was produced which
was released for public consultation between 26th October
and 23rd November 2016. In total, 58 comments were sub-
mitted by external stakeholders. These were individually
addressed during theMTACmeeting held on 16thDecember
2016. The comments related to recommendations based on
evidence on devices no longer in use, suitability of a single
technology assessment, factors other than battery capacity
affect battery longevity, costmodelling andmatters of fact or
lack of clarity in the draft guidance. Some of the comments
resulted in minor amendments to the guidance to further
clarify the committee’s considerations.
6.2 Final NICE Guidance
In December 2016, NICE made the following recommen-
dations concerning the use of ENDURALIFE-powered
CRT-D devices for treating heart failure:
1.1 The case for adopting ENDURALIFE-powered CRT-
D devices for treating heart failure is supported by the
published evidence. Extended battery life is of
clinical and patient benefit and associated with fewer
replacement procedures.
1.2 ENDURALIFE-powered CRT-Ds should be consid-
ered as an option in people offered CRT-D devices in
line with NICE technology appraisal guidance on
ICDs and cardiac resynchronisation therapy.
1.3 Cost modelling was based on published data using
predecessor devices, and showed that the price and
lifespan of theCRT-Dhave the greatest effect on overall
treatment costs. Assuming an average selling price of
£12,404 across different devices, usingENDURALIFE-
powered CRT-Ds may save between £2120 and £5627
per patient over 15 years through a reduction in the need
for replacement procedures. This could save the NHS in
England around £6 million in the first 5 years.
Following the resolution stage, it was concluded that
recommendation 1.3 contained points that required clari-
fication through minor revisions which did not affect the
Committee’s recommendations [31].
7 Key Challenges and Learning Points
The key challenge faced by the EAC and the MTAC was
the applicability of the available evidence to CRT-D
devices on the market today. The evidence presented for
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CRT-D longevity was for devices implanted in around
2008–2010. Many of these devices are no longer marketed.
In addition, it is likely that there have been numerous
innovations across different manufacturers and that these
innovations are unlikely to be limited to the battery alone.
The manufacturer’s de novo economic model had some
limitations and weaknesses. The EAC liaised with clinical
experts to decide which study should be used to obtain data
on rates of complications associated with CRT-D device
replacement procedures. In addition, the EAC obtained list
prices for ENDURALIFE-powered and comparator CRT-D
devices, obtained warranty data from comparator manu-
facturers and NHS reference costs. All the extra informa-
tion obtained by the EAC was substituted into the formulae
in the model and threshold analysis, using the average
selling price of ENDURALIFE-powered CRT-D devices,
and sensitivity analysis for complication rates was carried
out by the EAC.
The MTAC considered that the 6-year time horizon
made the cost case uncertain and asked the EAC to carry
out further work. The EAC extrapolated CRT-D lifespan to
15 years using a survival profile for comparator devices. In
addition, the EAC contacted NICOR to obtain unpublished
data in confidence on patient survival for patients aged
50–84 years at primary implantation. Using these data, the
EAC extrapolated patient survival to 15 years.
Evidence submitted for this MTG included CRT-D
devices that are no longer marketed. However, it was noted
by MTAC that this was unavoidable owing to the follow-
up time required to study battery life. The MTAC was
advised by clinical experts that published, peer-reviewed
clinical studies are a more reliable source of information
than unpublished, extrapolated and predicted lifespan data.
8 Conclusion
ENDURALIFE-powered CRT-Ds received a positive rec-
ommendation from NICE and should be considered as an
option for people requiring CRT-D devices in line with
previous NICE technology appraisal guidance [7]. Pub-
lished evidence showed superiority of ENDURALIFE-
powered CRT-Ds implanted in the period 2008–2010 in
terms of longevity. The EAC highlighted its uncertainty of
the applicability of the evidence to CRT-D devices mar-
keted today. However, the MTAC noted this was
unavoidable due to the follow-up time required to study
battery life. In addition, the EAC noted whether differences
in longevity between ENDURALIFE-powered CRT-Ds
and comparators lead to a reduction in replacement pro-
cedures depends on patient life expectancy. ENDUR-
ALIFE-powered CRT-Ds were shown to be cost saving
when compared to comparator CRT-Ds through a reduction
in the need for replacement procedures. Clinical experts
informed MTAC that increased battery life is an important
patient benefit. However, in practice the risk of pressure on
clinical services, due to possible future device-related
technical failure leading to recall and subsequent replace-
ment, is reduced by using CRT-Ds from more than one
manufacturer.
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